Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 3/20 | 0.66 |
| ▸ | MAOB | P27338 | 3/20 | 0.66 |
| ▸ | FABP1 | P07148 | 1/20 | 0.66 |
| ▸ | FABP6 | P51161 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30487250 | 1.00 | CXCR4 (0.68) | CXCR4CYP1A2MAOAMAOBFABP1 | |
| SCHEMBL3955545 | 0.83 | ALDH1A1 (0.65) | CXCR4CYP1A2MAOAMAOBFABP1 | |
| SCHEMBL1244338 | 0.83 | MAOA (0.70) | CYP1A2MAOAMAOBNPC1RAB9A | |
| SCHEMBL29351380 | 0.81 | CXCR4 (1.00) | CXCR4CYP1A2FABP1FABP6NPC1 | |
| SCHEMBL589266 | 0.81 | CXCR4 (1.00) | CXCR4CYP1A2FABP1FABP6NPC1 | |
| SCHEMBL29846220 | 0.81 | MAOA (0.68) | CYP1A2MAOAMAOBNPC1RAB9A | |
| SCHEMBL23938004 | 0.81 | NPC1 (0.62) | CXCR4CYP1A2MAOAMAOBFABP1 | |
| SCHEMBL4777942 | 0.81 | MAOA (0.53) | CXCR4CYP1A2MAOAMAOBFABP1 | |
| SCHEMBL15830499 | 0.81 | NOS2 (0.67) | CYP1A2MAOAMAOBNPC1RAB9A | |
| SCHEMBL1108639 | 0.81 | NPC1 (0.62) | CXCR4CYP1A2MAOAMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110563640-B | Dehydroabietyl pyridine amide compound and preparation method and application thereof | 南京林业大学 | 2021-03-12 | — | — | CN | claimed |
| CN-110563640-A | Dehydroabietyl pyridine amide compound and preparation method and application thereof | 南京林业大学 | 2019-12-13 | — | — | CN | claimed |
| US-8182718-B2 | Ligand exchange thermochromic systems and high ε ligands for same | PLEOTINT, L.L.C. (US) | 2012-05-22 | — | — | US | claimed |
| CN-116606292-A | Pyrido [1,2-a ] pyrimidinone derivatives containing sulfonamide unit, preparation method and application thereof | 贵州大学 | 2023-08-18 | — | — | CN | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| CN-114380822-A | CDKs inhibitor of beta-carboline mother nucleus, preparation method and anti-tumor application thereof | 中国人民解放军北部战区总医院 | 2022-04-22 | — | — | CN | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3856726-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | Black Diamond Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-110563640-B | Dehydroabietyl pyridine amide compound and preparation method and application thereof | 南京林业大学 | 2021-03-12 | — | — | CN | disclosed |
| CN-110563640-B | Dehydroabietyl pyridine amide compound and preparation method and application thereof | 南京林业大学 | 2021-03-12 | — | — | CN | disclosed |
| WO-2020068867-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-7538931-B2 | Ligand exchange thermochromic systems containing exchange metals | PLEOTINT, L.L.C. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7525717-B2 | reversible; laminated; transition metal ion coordinated with a high epsilon ligand and a low epsilon ligand; polymer; separator; variable light transmission windows; polyvinyl butyral; nickel or cobalt iodide ligands; diol, triol or polyol ligands | PLEOTINT, L.L.C. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080105851-A1 | Exhibiting a reversible change in absorbance of electromagnetic radiation as the temperature of the system is reversibly changed; comprising a transition metal ion and a ligand | PLEOTINT, LLC (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080106781-A1 | LIGAND EXCHANGE THERMOCHROMIC SYSTEMS CONTAINING EXCHANGE METALS | PLEOTINT, LLC (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080100902-A1 | LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS | PLEOTINT, LLC (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080100903-A1 | MULTI-LAYER LIGAND EXCHANGE THERMOCHROMIC SYSTEMS | PLEOTINT, LLC (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008028128-A1 | LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS | PLEOTINT, L.L.C. (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20040087798-A1 | Novel amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | CXCR4 4839/4885CYP1A2 2136/4885MAOA 2243/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | CXCR4 4839/4885CYP1A2 2136/4885MAOA 2243/4885 |
| US-20040087798-A1 | Novel amide compounds | H1-2, H1-0, H1-3 | CXCR4 1173/4885CYP1A2 1021/4885MAOA 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.